{"version":"1.0","provider_name":"\u541b\u5b9e\u751f\u7269","provider_url":"https:\/\/www.junshipharma.com\/en\/","title":"Junshi Biosciences Announces Approval for Marketing of VV116 in China - \u541b\u5b9e\u751f\u7269","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"qmUfSySXCa\"><a href=\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/\">Junshi Biosciences Announces Approval for Marketing of VV116 in China<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/embed\/#?secret=qmUfSySXCa\" width=\"600\" height=\"338\" title=\"&#8220;Junshi Biosciences Announces Approval for Marketing of VV116 in China&#8221; &#8212; \u541b\u5b9e\u751f\u7269\" data-secret=\"qmUfSySXCa\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg","thumbnail_width":1620,"thumbnail_height":1079,"description":"SHANGHAI, China, January 30, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the \u201cNMPA\u201d) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (\u201cCOVID-19\u201d)."}